Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Chronic Kidney Disease–associated Pruritus (CKDaP) remains one of the most distressing and underrecognized complications among patients on maintenance hemodialysis. Despite its high prevalence and significant effect on sleep and overall well-being, regional data from low and middle-income countries, including India, remain limited. This study aimed to determine the prevalence, severity, and influencing factors of CKDaP and to evaluate its impact on quality of life and sleep using validated assessment tools.
Patient demographics, dialysis parameters (vintage, frequency, and adequacy measured by Kt/V), and relevant biochemical variables were extracted from the hospital’s electronic medical records (EMR). The 12-Item Pruritus Severity Scale and the 5D Itch Scale were employed to assess pruritus severity and multidimensional burden. Quality of life was evaluated using the Dermatology Life Quality Index (DLQI) and Skindex-16, while sleep quality was measured using the Pittsburgh Sleep Quality Index (PSQI). Statistical analyses were performed using SPSS version 21 to examine correlations between pruritus severity, dialysis parameters, and laboratory profiles, with significance set at p<0.05.
Among 216 hemodialysis patients, the prevalence of CKDaP was 60.6%, with mild, moderate, and severe pruritus observed in 37.0%, 19.9%, and 3.7% of participants, respectively. Most affected patients were male and aged 50–79 years, with diabetic kidney disease as the leading CKD etiology. Dialysis adequacy, frequency, and duration showed no significant differences between pruritic and non-pruritic groups. Laboratory variables, including hemoglobin, albumin, calcium, phosphorus, and parathyroid hormone levels, were also not significantly associated with pruritus. The 5D Itch Scale showed that 52.9% of patients with moderate-to-severe pruritus experienced prolonged daily itching, most commonly over the back (77.9%), with no significant change over time (p=0.18). Quality-of-life assessment revealed a substantial burden: 75.5% reported impairment on the Dermatology Life Quality Index (DLQI), and Skindex-16 indicated marked emotional and functional distress among those with higher pruritus severity. Sleep quality, measured by the Pittsburgh Sleep Quality Index (PSQI), worsened significantly with increasing pruritus intensity (p<0.01).
CKDaP is highly prevalent among Indian hemodialysis patients, significantly affecting quality of life and sleep, even in the absence of clear biochemical predictors. These findings highlight the need for routine screening and targeted management strategies in dialysis centers, particularly in resource-constrained settings. By documenting region-specific patterns and burdens, this study contributes valuable data to the global understanding of CKDaP and supports the prioritization of symptom-based interventions in chronic kidney disease care.
